A selected list of recent publications and books by Dr Paul Morrison on different aspects of psychiatry, including cannabidiol (CBD), esketamine, nitric oxide, psilocybin and oxytocin.
The Maudsley Guidelines on Advanced Prescribing in Psychosis
Paul Morrison, David M. Taylor, Phillip McGuire
ISBN: 978-1-119-57843-7 January 2020 Wiley-Blackwell
Jauhar S., & Morrison PD.(2019) Esketamine for treatment resistant depression. BMJ 366: l5572.
Davies C., Paloyelis Y., Rutigliano G., Cappuciati M., De Michelli A., Ramello-Cravaro V., Provenzani U., Antoniades M., Modinos G., Oliver D., Stahl D., Murgluia S., Zelaya F., Allen P., Shergill S., Morrison PD.,Williams S., Taylor D., McGuire P., and Fusar-Poli P. (2019) Oxytocin modulates hippocampal perfusion in people at clinical high risk for psychosis. Neuropsychopharmacology. PMID: 30626906
Hobbs M., Kalk NJ., Morrison PD& Stone JM. (2018) Spicing it up – synthetic cannabinoid receptor agonists and psychosis – a systematic review. European Neuropsychopharmacology.PMID: 30454908
Stone JM., Roux S., Taylor D. & Morrison PD. First generation vs. second generation long acting injectable antipsychotic drugs and time to relapse. Therapeutic Advances in Psychopharmacology. (in-press).
Gabay A., Carhart-Harris R., Mazibuko N., Kempton M., Morrison PD., Nutt D., and Mehta MA (2018) Psilocybin and MDMA reduce costly punishment in the Ultimatum Game. Sci. Rep 8:8236
Mehta MA., Schmechtig A., Kotoula V., McColm J., Jackson K., Brittain C., Tauscher-Wisniewski S., Kinon BJ., Morrison PD., Pollak T., Mant T., Williams SCR. &. Schwarz AJ. (2018) Group II Metabotropic Glutamate Receptor Agonist Prodrugs LY2979165 and LY2140023 attenuate the Functional Imaging Response to Ketamine in Healthy Subjects. Psychopharmacology (Berl). 235: 1875-1886.
Morrison PD. & Murray RM (2018) The anti-psychotic landscape: dopamine and beyond. Therapeutic Advances in Psychopharmacology 8, 127-35.
McGuire P., Robson P., Wieslaw JC., Vasile D., Morrison PD., Barron R., Taylor A. & Wright S., (2018). Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. Am J. Psychiatry. PMID: 29241357
Hundal H., Lister R., Evans N., Antley A., Englund A., Murray RM., Freeman D. & Morrison PD (2017) The effects of cannabidiol on persecutory ideation and anxiety in a high trait paranoid group. J Psychopharmacology [PMID: 29086614]
Barkus E., Morrison P., DiForti M & Murray RM (2016) Are deficits in cognition associated with psychotic like experiences after cannabis. Hum Psychopharmacol. 31, 402-11.
Stone JM., Morrison PD., Koychev I, Gao F, Reilly TJ, Kolanko M, Mohammadinasab A, Kapur S, McGuire PK (2016) The effect of sodium nitroprusside on psychotic symptoms and spatial working memory in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. Psychol Med. [PMID 27655012]
Tunbridge EM., Dunn G, Murray RM., Evans N, Lister R, Stumpenhorst K, Harrison PJ, Morrison PD & Freeman D (2015) Genetic moderation of the effects of cannabis: Catechol-O-methyltransferase (COMT) affects the impact of ∆9-tetrahydrocannabinol (THC) on working memory performance but not on the occurrence of psychotic experiences. J. Psychopharmacology [PMID: 26464454]
Englund A., Atakan Z., Kralj A., Tunstall N., Murray RM. & Morrison PD (2015) The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial. J. Psychopharmacology [PMID: 26577065]
Morrison PD., Bhattacharryya S., and Murray RM (2014) Recreational cannabis: The risk of schizophrenia. Handbooks in Psychopharmacology [in-press].
Freeman D., Dunn G., Murray RM., Evans N., Lister R., Antley A., Slater M., Godlewska B., Cornish R., Williams J., Di Simplicio M., Igoumenou A., Brenneisen R., Tunbridge EM., Harrison PJ., Harmer CJ., Cowen P., and Morrison PD. (2014) How Cannabis Causes Paranoia: Using the Intravenous Administration of Δ9-Tetrahydrocannabinol (THC) to Identify Key Cognitive Mechanisms Leading to Paranoia. Schizophrenia Bulletin [PMID: 25031222].
Nottage JF., Stone JM., Murray RM., Sumich A., Bramon-Bosch E., ffytche DH., and Morrison PD. (2014) Delta-9-Tetrahydrocannabinol, neural oscillations above 20 Hz and induced acute psychosis. Psychopharmacology. [PMID: 25038870]
Freeman D, Morrison PD., Murray RM., Evans, N., Lister, R. & Dunn, G. (2013) Persecutory ideation and a history of cannabis use. Schizophrenia Research [PMID: 23806582].
Murray RM, Paparelli A, Morrison PD, Marconi A, Di Forti M (2013) What can we learn about schizophrenia from studying the human model, drug-induced psychosis? Am J Med Genet B Neuropsychiatr Genet. 2013 Oct;162B(7):661-70.
Perkins, A. M., Ettinger, U., Weaver, K., Schmechtig, A., Schrantee, A., Morrison, P. D., Sapara, A., Kumari, V., Williams, S. C. R., & Corr, P. J. (2013) Advancing the defensive explanation for anxiety disorders: lorazepam effects on human defense are systematically modulated by personality and threat-type. Translational Psychiatry [PMID 23591970]
Englund A., Morrison PD., Nottage J., Hague D., Kane F., Bonaccorso S et al (2013) Cannabidiol inhibits THC-elicited psychosis and hippocampal-dependent memory impairment. J Psychopharmacology 27, 19-27.
Stone JM., Morrison PD, Brugger S, Nottage J, Bhattacharyya S, Sumich A et al (2012). Communication Breakdown: delta-9-tetrahydrocannabinol effects on pre-speech neural coherence. Molecular Psychiatry 17, 568-9.
Morrison PD, Nottage J, Stone JM, Bhattacharyya S, Tunstall N, Brenneisen R et al. (2011) Disruption of frontal theta coherence by delta-9-tetrahydrocannibinol is associated with positive psychotic symptoms. Neuropsychopharmacology 36, 827-36.
Sadiq Z & Morrison PD (2011) The Management of Cannabis Associated Mental Health Problems. In Practice in Mental Health- Substance Use. Ed Cooper DB. Radcliffe.
Neidpath A & Morrison PD (2010) It’s a lack of balance that makes skunk cannabis do harm. New Scientist 2744, 22-23.
Morrison P.D. and Murray R.M (2009). From real world events to psychosis: the emerging neuropharmacology of delusions. Schizophrenia Bulletin. 35, 668-74.
Luzi S, Morrison P.D., Powell J., DiForti M. and Murray R.M. (2008) What is the mechanism wherby cannabis use increases risk of psychosis? Neurotox. Res. 14, 105-12.
Henquet C, DiForti M, Morrison P.D., Kupper R. and Murray R.M. (2008) Gene-environment interplay between cannabis and psychosis. Schizophrenia Bulletin 34, 1111-21.
Murray R.M, Morrison P.D., Henquet C. and DiForti M. (2007) Cannabis, the mind and society: The Hash Realities. Nature Reviews Neuroscience. 11, 885-95.
Stone J.M., Morrison P.D. and Pilowsky L.S. (2007) Glutamate and dopamine dysregulation in schizophrenia – a synthesis and selective review. J. Psychopharmacology 21, 440-52.
Morrison P.D. and Murray R.M. (2007) Cannabinoid Psychoses. The Biochemist 29, 8-10.
Morrison P.D. and Murray R.M. (2005) Schizophrenia. Current Biology 15, R980-984.
Morrison P.D., Allardyce J. and McKane J.P. (2002) Fear Knot. Neurobiological disruption of long-term fear memory. British Journal of Psychiatry 180, 195-97.